Joseph Thome
Stock Analyst at TD Cowen
(2.59)
# 2,219
Out of 4,761 analysts
22
Total ratings
47.37%
Success rate
17.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $16.27 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $361.10 | +10.77% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $12.68 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.37 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $35.32 | -3.74% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $128.60 | -30.02% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $2.97 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $2.36 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $50.69 | -40.82% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $5.72 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.73 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.54 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.47 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $137.75 | -5.63% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.17 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.04 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.29 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $16.27
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $361.10
Upside: +10.77%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $12.68
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.37
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $35.32
Upside: -3.74%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $128.60
Upside: -30.02%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $2.97
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.36
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $50.69
Upside: -40.82%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.72
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $39.73
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.54
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.47
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $137.75
Upside: -5.63%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.17
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.04
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.29
Upside: -